Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

@article{Sabia2004EffectOA,
  title={Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects},
  author={Helene D Sabia and Gangadhar Sunkara and Monica A. LIGUEROS-SAYLAN and Yibin Wang and Harold T. Smith and James E T McLeod and Pratapa P Prasad},
  journal={European Journal of Clinical Pharmacology},
  year={2004},
  volume={60},
  pages={407-412}
}
The objective of the study was to determine the effect of a potent and selective CYP2C9 inhibitor, sulfinpyrazone (Anturane), on the pharmacokinetics of nateglinide (Starlix), a novel antidiabetic drug which is primarily (~70%) metabolized via CYP2C9. This was a randomized, open-label, two-period, crossover study in 18 healthy volunteers. Nateglinide was administered as a single 120-mg oral dose alone (reference) on day 1 or in combination with sulfinpyrazone (test) on day 7, following twice… CONTINUE READING